Navigation Links
Haemonetics and Octapharma AG Announce Plasma Collection Technology Contract

BRAINTREE, Mass., May 29 /PRNewswire-FirstCall/ -- Haemonetics Corporation and Octapharma AG announced today the signing of a multi-year supply contract appointing Haemonetics as Octapharma's preferred provider of plasma collection technology in the United States. Under the agreement, Octapharma will use Haemonetics' technology to separate plasma from donor blood at its U.S. plasma collection centers. Plasma is the source of numerous proteins used for drug development and therapeutic purposes. These proteins include albumin, clotting factors, and intravenous immunoglobulin ("IVIG").

Octapharma, a Swiss-based company, is an independent plasma fractionation specialist, the largest privately owned plasma products company in the world. One of the top global plasma fractionators, Octapharma reported fiscal 2006 sales of euro 752 million with 37% growth year over year and has averaged revenue growth of 20% since 1995. The company owns five state of the art fractionation facilities in Austria, France, Sweden, Germany, and Mexico.

"In order to meet the increasing demand for Octapharma bio-pharmaceutical products, a key focus of the company is to extend production capacities in all our facilities. Octapharma has already started its partial vertical integration of owning plasma centers in Europe and the U.S., and it is our goal to source 50% of the plasma needed from our own centers by 2010," said Karl Erik Clausen, Chief Financial Officer of Octapharma. "Through our U.S. subsidiaries, Plasma Procurement Services, Inc. will secure Octapharma's supply of source plasma in the United States and Octapharma is pleased to be expanding its relationship with Haemonetics."

Stephen Swenson, General Manager of Global Plasma for Haemonetics, said, "Octapharma is a premier global plasma collector and fractionator, and it is the fastest growing company in the industry. We have been extremely pleased with the results relating to the European agreement we signed with Octapharma last year and are delighted to be expanding our relationship into the U.S."

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at


Julie Fallon

Tel. (781) 356-9517

Alternate Tel. (617) 320-2401

SOURCE Haemonetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Haemonetics(R) Appoints Peter Allen as Chief Marketing Officer
2. Haemonetics Becomes Preferred Provider of Plasma Collection Products to Octapharma Europe
3. Haemonetics Announces New Subsidiary, Haemonetics Software Solutions
4. Octapharma Joins Biotechnology Industry Organization
5. FASgen Diagnostics, LLC Announces Production and Investment Agreement With Tetracore, Inc.
6. China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml)
7. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
8. Favrille Announces Workforce Reduction
9. AMT Announces Presentations During the 11th Annual Meeting of the ASGT
10. Genmab Announces 2008 First Quarter Results
11. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update
Post Your Comments:
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
Breaking Biology Technology:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):